OncoMatch/Clinical Trials/NCT06431685
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
Is NCT06431685 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Pemetrexed and Sintilimab for nsclc.
Treatment: Pemetrexed · Sintilimab · Chemotherapy — This phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–3(Limited self-care)
Lab requirements
Blood counts
Hemoglobin ≥80 g/L, neutrophils ≥1.5×10^9/L and platelets ≥70×10^9/L
Kidney function
Cr≤ULN × 1.5, endogenous creatinine clearance (Ccr)≥55 ml/min
Liver function
total bilirubin ≤ULN × 1.5; ALT, AST≤ULN × 2.5; (In case of liver metastasis, total bilirubin should not be higher than 3 times the upper normal limit, and transaminase should not be higher than 5 times the upper normal limit)
bone marrow and liver and kidney function met the following criteria: Hemoglobin ≥80 g/L, neutrophils ≥1.5×10^9/L and platelets ≥70×10^9/L; Cr≤ULN × 1.5, endogenous creatinine clearance (Ccr)≥55 ml/min; total bilirubin ≤ULN × 1.5; ALT, AST≤ULN × 2.5; (In case of liver metastasis, total bilirubin should not be higher than 3 times the upper normal limit, and transaminase should not be higher than 5 times the upper normal limit)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify